Latest news articles

Added 1 month ago Drug news

Real-World data analysis of Eliquis for the treatment of venous thromboembolism in patients with active cancer.- BMS + Pfizer

The Bristol-Myers Squibb-Pfizer Alliance announced results from retrospective real-world data analyses reporting outcomes on the safety and effectiveness of Eliquis...

Added 2 months ago Drug news

Actelion Pharma withdraws filing of Opsumit for CTEPH

Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced its decision to voluntarily withdraw...

Added 3 months ago Drug news

FDA approves Xarelto to help prevent blood clots in acutely ill medical patients.- BayerHealthCare + Janssen R&D

Bayer AG and its development partner Janssen Research & Development, LLC announced that the FDA has approved rivaroxaban (Xarelto) for...

Search all news articles for Pulmonary heart disease

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

ESICM LIVES Highlights

ESICM LIVES Highlights

ESICM LIVES Congress 2018: Bringing you the latest news and insights from the 31st ESICM LIVES Congress, 20–24 October 2018 Paris, France.

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

Load more


Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots) and deep vein thrombosis (DVT) in people aged 16 and over in hospital.

Added 9 years ago

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R

The scope of this focused update of the 2014 AF Guideline includes revisions to the section on anticoagulation (because of the approval of new medications and thromboembolism protection devices), revisions to the section...

Added 5 months ago

British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE)

The British Thoracic Society (BTS) Guideline for the initial OP management of PE provides guidance on how to risk-stratify patients with suspected and confirmed PE and subsequently manage them in an OP or ambulatory care setting.

Added 1 year ago

Search all guidelines for Pulmonary heart disease

Journal articles

Analysis of the venous thromboembolic risk associated with severe postpartum haemorrhage in the NOHA First cohort

Severe postpartum haemorrhages (PPH) are responsible for maternal morbidity/mortality. Their complex management sometimes requires haemostatic supplementation, and therapeutic trials on fibrinogen or activated factor VII...

Added 1 month ago

Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.

Background: Over the last ten years, a new class of drugs, known as the direct-acting oral anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the older generation anticoagulants, DOACs require...

Added 2 months ago

ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison.

Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at preventing the atherothrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations.

Added 5 months ago

Search all journal articles for Pulmonary heart disease

Clinical trials

A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)

This study is to compare the study drug BAY1213790 to existing therapies, ie Enoxaparin or Apixaban for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).

Added 2 years ago

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (EinsteinChoice)

This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.
Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism)...

Added 6 years ago

Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II)

In this study the investigators want to look at whether using aspirin instead of rivaroxaban (after initial treatment with rivaroxaban) works as well at preventing blood clots while also reducing risk of bleeding...

Added 1 year ago

Search all clinical trials for Pulmonary heart disease
Adam Jeffery

What is Overdiagnosis?

Overdiagnosis is the diagnosis of disease that will cause neither morbidity nor mortality during a patient’s lifetime. Doctors are trained to listen, examine, test, diagnose and treat patients, but we are not warned of the possible dangers of “diseases”, the diagnosis of which will not benefit the patient and may also lead to harm. I would argue that the Hippocratic oath, in particular “Primum non nocere” (first, do no harm) should be at the forefront of every clinician’s mind when seeing patients.